MNKD

Business Context and Reporting Period

Company: MannKind Corporation (MannKind)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: MannKind is a biopharmaceutical company in the development stage, focused on therapeutic products for diabetes and cancer. Its lead product candidate, AFREZZA (an ultra rapid-acting inhaled insulin), is awaiting FDA approval. The company has incurred cumulative net losses of $1.7 billion since inception and has no commercial product revenue.

Key Financial Metrics

Note: All figures in thousands except per share data. Net loss per share (basic and diluted) was $(0.40) for the quarter and $(1.17) for the nine-month period.

Material Changes vs. Prior Period

• Revenue: Remained negligible ($93k for nine months 2010 vs. $0 for nine months 2009).
• Net Loss: Improved slightly for the quarter ($(45.3M) vs. $(45.6M) in 2009) and significantly for the nine-month period ($(132.3M) vs. $(160.6M) in 2009).
• Operating Expenses:
  • R&D: Increased 3% for the quarter ($31.4M vs. $30.5M) due to raw material purchases, but decreased 22% for the nine months ($88.1M vs. $113.2M) due to reduced clinical costs and workforce reductions.
  • G&A: Decreased 9% for the quarter and 20% for the nine months, driven by lower salary costs and professional fees.
• Liquidity: Cash and cash equivalents increased from $30.0 million (Dec 31, 2009) to $97.9 million (Sep 30, 2010), primarily due to financing activities.
• Debt: Senior convertible notes increased from $112.8 million to $209.0 million following a new $100 million issuance in August 2010. Related party debt increased from $165.0 million to $252.0 million.

Guidance, Outlook, and Risks

Regulatory Outlook: The FDA accepted MannKind's reply to a Complete Response letter regarding the AFREZZA New Drug Application (NDA) in July 2010, setting a target action date of December 29, 2010. Approval is not guaranteed.

Liquidity and Capital Resources:

• Management believes existing capital resources (approx. $98 million cash + $98 million available borrowing capacity) will fund operations into the third quarter of 2011.
• There is substantial doubt about the company's ability to continue as a going concern if additional capital is not raised through equity, debt, or strategic collaborations.
• On August 10, 2010, the company entered into agreements to sell up to 18.2 million shares to Seaside 88, LP and a corresponding purchase agreement with The Mann Group. The first tranche of 700,000 shares was sold to Seaside on October 20, 2010, for net proceeds of $4.3 million.

Risks and Contingencies:

• Going Concern: Significant accumulated deficit ($1.7 billion) and reliance on future financing.
• Legal Proceedings: A former employee filed a lawsuit alleging wrongful termination and retaliation; the company intends to defend vigorously.
• Supply Chain: Binding annual commitment for insulin purchases totaling $83 million through 2012.
• Stock Dilution: Substantially all authorized but unissued shares are reserved for future issuance under equity plans and debt conversion.

Investor Verification Checklist

• FDA Decision Date: Verify the outcome of the FDA's target action date of December 29, 2010, for the AFREZZA NDA.
• Cash Burn Rate: Monitor monthly cash usage to confirm if the runway extends beyond Q3 2011 as projected.
• Financing Execution: Track the execution of the Seaside 88, LP stock purchase agreement and any additional equity or debt offerings.
• Debt Covenants: Review terms of the $350 million related-party loan with The Mann Group, specifically prepayment rights and interest rate adjustments upon default.
• Legal Status: Monitor the status of the Arditi v. MannKind Corporation litigation.